FDA Grants Accelerated Approval to Iberdomide for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM). This combination is indicated for patients who have received at least one prior line of therapy. Iberdomide is the first approved cereblon E3 ligase modulator (CELMoD) agent, introducing a novel drug class for myeloma treatment.